40 results
8-K
CHRS
Coherus Biosciences Inc
14 Apr 20
Entry into a Material Definitive Agreement
7:43am
to the COVID-19 global pandemic, the Company is supplementing the risk factors previously disclosed in Item 1A. of its Annual Report on Form 10-K for the year … -19 pandemic.
We are subject to risks related to public health crises such as the global pandemic associated with the novel coronavirus
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
13 Jan 22
Entry into a Material Definitive Agreement
4:39pm
and regions worldwide. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi … and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; risks relating to the COVID-19 pandemic
8-K
EX-99.1
sl0u1
8 Nov 22
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
4:01pm
8-K
EX-99.1
pv2bgou3t0ahqxaobkp
6 May 21
Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
4:24pm
8-K
EX-99.2
r1eq9la c3t87
2 Feb 21
Entry into a Material Definitive Agreement
8:45am
8-K
EX-99.1
pugsybaxu97kndb u5v
27 Oct 23
Regulation FD Disclosure
4:19pm
8-K
EX-99.1
xryvf65mtyw vlisbm
4 Aug 22
Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update
4:25pm